Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. develops gene therapies for blindness diseases through a modifier gene therapy platform designed to address inherited and multifactorial retinal disorders. Company news commonly covers programs such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease.
Recurring updates include clinical trial data and dosing milestones, clinical and regulatory disclosures, operating and financial results, investor presentations, convertible-note financing, shareholder voting matters, capital-structure actions, and governance matters tied to the company's Nasdaq-listed common stock.
Ocugen (NASDAQ: OCGN) will participate in two August 2026 investor events focused on its modifier gene therapy platform for blindness diseases. The company will join a panel at the Oppenheimer 4th Annual Biotech in the Berkshires Summit on August 4 in Lenox, MA, and host a fireside chat at the Canaccord 46th Annual Growth Conference on August 11 in Boston, MA. A live webcast and 30-day replay of the Canaccord session will be available via the Investors section of Ocugen’s website.
Ocugen (NASDAQ: OCGN) announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational gene therapy OCU410 for treating geographic atrophy (GA) secondary to dry age-related macular degeneration.
According to Ocugen, the RMAT designation, based on Phase 2 data showing clinically meaningful efficacy and a favorable safety profile with no serious drug-related adverse events reported, may enable an expedited regulatory path. The company recently aligned with the FDA on the design of a Phase 3 registrational trial, which it expects to initiate in the third quarter of 2026, and anticipates filing a Biologics License Application (BLA) in 2028.
Ocugen (NASDAQ: OCGN) announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 6, 2026 to discuss its second quarter 2026 financial results and provide a business update. A pre-market earnings announcement will be issued the same day.
According to Ocugen, U.S. participants can dial (800) 715-9871 and international participants can dial (646) 307-1963, using Conference ID: 2222566. A live and archived webcast, as well as a replay of the call, will be available in the events section of the Ocugen investor website.
Ocugen (NASDAQ: OCGN) signed a binding term sheet with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding to negotiate an exclusive license for OCU400, a modifier gene therapy for Retinitis Pigmentosa, in the Middle East and North Africa (MENA) region.
According to Ocugen, the anticipated license agreement would provide up to $4 million in upfront and near-term development milestone payments, cumulative sales milestones up to $255 million, and a 22% royalty on net sales generated by its partner. Ocugen would also manufacture commercial supply of OCU400 under a related supply agreement. The company continues to advance OCU400 in its Phase 3 liMeliGhT trial, with topline data expected in 1Q 2027 followed by a planned BLA submission. Execution of the definitive agreement is expected within 90 days.
Ocugen (NASDAQ:OCGN) will participate in several ophthalmology-focused conferences in July 2026, highlighting its modifier gene therapy platform and retinal disease programs.
Events include Piper Sandler Virtual Ophthalmology Day, OIS Retina Innovation Summit, and ASRS presentations featuring OCU410 Phase 2 ArMaDa 1-year results and Phase 1/2 safety and imaging analyses.
Ocugen (NASDAQ: OCGN) will present its modifier gene therapy platform and retinal disease innovation at multiple June 2026 investor and industry conferences.
Events include the Noble Capital Markets Emerging Growth Virtual Equity Conference, Clinical Trials at the Summit 2026, and the BIO International Convention, with webcast access for Noble.
Ocugen (NASDAQ: OCGN) closed a private offering of $130.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 to qualified institutional buyers under Rule 144A, including a $15.0 million over-allotment option.
The notes were priced at 90% of principal, generating approximately $112.6 million in net proceeds. Ocugen used about $32.7 million to fully repay its Avenue Capital loan, including interest and fees, and plans to use the remaining proceeds for general corporate purposes. According to Ocugen, this financing extends its anticipated cash runway into 2028 to support three late-stage programs and the goal of filing three BLAs by 2028.
Ocugen (NASDAQ: OCGN) will present its modifier gene therapy platform at scientific and investor events in May 2026.
Presentations include the Retina World Congress Inherited and Rare Retinal Diseases Session on May 14, 2026, and the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026, with a webcast and 30-day replay.
Ocugen (NASDAQ: OCGN) reported Q1 2026 results and a business update on May 5, 2026. Key clinical highlights include a statistically significant 31% reduction in GA lesion growth at 12 months for OCU410 (optimal dose) and enrollment completion for Phase 3 OCU400 (liMeliGhT, N=140) and OCU410ST (N=63). The company closed a private offering of $115M convertible notes (6.75% due 2034) expected to increase cash to $112.1M at close and extend runway into 2028, subject to closing conditions.
Ocugen (NASDAQ: OCGN) priced $115.0 million aggregate principal amount of 6.75% convertible senior notes due 2034 in a private Rule 144A offering, with a 13-day option for an additional $15.0 million. The notes sold at 90% of principal.
Ocugen expects closing on May 7, 2026, with estimated net proceeds of approximately $99.5 million (or $112.6 million if the option is exercised). Approximately $32.7 million of net proceeds are planned to repay the Avenue loan; remaining proceeds are for general corporate purposes. Initial conversion price is approximately $2.68 per share (372.7866 shares per $1,000), convertible after May 15, 2027 or upon the reserved share effective date.